|

Insurance and Access Implications of an Over-the-Counter Switch for a Progestin-Only Pill

Jennifer McIntosh Britt Wahlin Kate Grindlay, Ibis Reproductive Health Myra Batchelder Daniel Grossman, University of California, San Francisco

First published online:

| DOI: https://doi.org/10.1363/4516413

Author's Affiliations

Jennifer McIntosh is visiting researcher at the Department of Pharmacy, Hospital Clínic, Barcelona, Spain. Britt Wahlin is director of development and communications, and Kate Grindlay is senior project manager, both at Ibis Reproductive Health, Cambridge, MA. Myra Batchelder is reproductive health consultant. Daniel Grossman is vice president for research, Ibis Reproductive Health, and assistant clinical professor, Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco.

Disclaimer

The views expressed in this publication do not necessarily reflect those of the Guttmacher Institute.